根据最新的财务报表(Form-10K),Kyowa Kirin Co., Ltd. 的总资产为 $0,净损失为 $0
KYKOY 的关键财务比率是什么?
Kyowa Kirin Co., Ltd. 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Kyowa Kirin Co., Ltd. 的收入按细分市场或地理位置如何划分?
Kyowa Kirin Co., Ltd. 最大收入来源是 Manufactured Product,在最近的收益报告中收入为 438,380,000,000。就地区而言, United States 是 Kyowa Kirin Co., Ltd. 的主要市场,收入为 238,907,000,000。
Kyowa Kirin Co., Ltd. 是否盈利?
不,根据最新的财务报表,Kyowa Kirin Co., Ltd. 的净损失为 $0
Kyowa Kirin Co., Ltd. 有负债吗?
不,Kyowa Kirin Co., Ltd. 的负债为 0
Kyowa Kirin Co., Ltd. 的流通股有多少?
Kyowa Kirin Co., Ltd. 的总流通股为 0
关键数据
前收盘价
--
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
--
股息收益率
--
每股收益(TTM)
--
市值
--
什么是 Kyowa Hakko Kogyo Co., Ltd.?
Kyowa Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 5,161 full-time employees. The firm operates in Pharmaceuticals business segment. The firm engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The firm has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The firm operates in Japan and overseas.